

Special Issue

Alzheimer's Disease—115 Years after Its Discovery

Message from the Guest Editors

It has been a long journey since Alois Alzheimer, a dedicated German physician, first linked Auguste Deter's symptoms of deteriorating memory, disorientation, decreasing speech abilities, and lack of judgment to the detection of two characteristic brain lesions, neurofibrillary tangles, and extracellular deposits that were later named senile plaques—a discovery that would make his name a household term throughout the world! Now, at 115 years after this discovery, the massive international research effort has contributed to uncovering several pieces of key information about the causes and accelerators of the development of Alzheimer's disease (AD) and its progression. In this Commemorative Special Issue, we intend to present an overview of the state-of-the-art of this interesting story including the important recent advances and the latest research and milestones in AD research. We welcome papers focused on (i) diagnostic tools; (ii) in vivo and in vitro models of the disease; (iii) molecular mechanisms underlying the onset and progression of the disease; and (iv) therapeutic strategies aimed to counteract the advances of AD.

Guest Editors

Dr. Susana Cardoso
Dr. Cristina Carvalho
Dr. Sónia Catarina Correia

Deadline for manuscript submissions

closed (31 December 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/68258

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).